PL3886858T3 - Związki do leczenia chorób oka związanych z nadmiernym unaczynieniem - Google Patents
Związki do leczenia chorób oka związanych z nadmiernym unaczynieniemInfo
- Publication number
- PL3886858T3 PL3886858T3 PL20838435.4T PL20838435T PL3886858T3 PL 3886858 T3 PL3886858 T3 PL 3886858T3 PL 20838435 T PL20838435 T PL 20838435T PL 3886858 T3 PL3886858 T3 PL 3886858T3
- Authority
- PL
- Poland
- Prior art keywords
- compounds
- treatment
- diseases associated
- eye diseases
- vascularisation
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 208000030533 eye disease Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19218062 | 2019-12-19 | ||
EP20156158 | 2020-02-07 | ||
PCT/EP2020/086993 WO2021123142A1 (en) | 2019-12-19 | 2020-12-18 | Compounds for treatment of eye diseases associated with excessive vascularisation |
Publications (1)
Publication Number | Publication Date |
---|---|
PL3886858T3 true PL3886858T3 (pl) | 2022-08-29 |
Family
ID=74141502
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL20838435.4T PL3886858T3 (pl) | 2019-12-19 | 2020-12-18 | Związki do leczenia chorób oka związanych z nadmiernym unaczynieniem |
Country Status (15)
Country | Link |
---|---|
US (2) | US11478465B2 (pl) |
EP (2) | EP4094765A1 (pl) |
JP (1) | JP2023509336A (pl) |
KR (1) | KR20220118419A (pl) |
CN (1) | CN114845718A (pl) |
AU (1) | AU2020408179A1 (pl) |
BR (1) | BR112022009192A2 (pl) |
CA (1) | CA3157394A1 (pl) |
DK (1) | DK3886858T3 (pl) |
ES (1) | ES2921360T3 (pl) |
IL (1) | IL293469B2 (pl) |
MX (1) | MX2022006439A (pl) |
PL (1) | PL3886858T3 (pl) |
WO (1) | WO2021123142A1 (pl) |
ZA (1) | ZA202204939B (pl) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117120035A (zh) | 2021-04-01 | 2023-11-24 | 活跃生物技术有限公司 | 用于眼部使用的拉喹莫德制剂 |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE9801474D0 (sv) | 1998-04-27 | 1998-04-27 | Active Biotech Ab | Quinoline Derivatives |
US6077851A (en) | 1998-04-27 | 2000-06-20 | Active Biotech Ab | Quinoline derivatives |
US6875869B2 (en) | 2002-06-12 | 2005-04-05 | Active Biotech Ab | Process for the manufacture of quinoline derivatives |
US9265725B2 (en) | 2002-10-25 | 2016-02-23 | Foamix Pharmaceuticals Ltd. | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
WO2008124828A1 (en) * | 2007-04-10 | 2008-10-16 | Myriad Genetics, Inc. | Methods for treating vascular disruption disorders |
EP2376456A2 (en) | 2008-12-17 | 2011-10-19 | Actavis Group Ptc Ehf | Highly pure laquinimod or a pharmaceutically acceptable salt thereof |
JP2013535437A (ja) * | 2010-07-09 | 2013-09-12 | テバ ファーマシューティカル インダストリーズ リミティド | 重水素化されたn−エチル−n−フェニル−1,2−ジヒドロ−4−ヒドロキシ−5−クロロ−1−メチル−2−オキソキノリン−3−カルボキサミド、その塩および使用 |
EP2463289A1 (en) | 2010-11-26 | 2012-06-13 | Almirall, S.A. | Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors |
EP2527344A1 (en) | 2011-05-25 | 2012-11-28 | Almirall, S.A. | Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases |
EP2537517A1 (en) * | 2011-06-22 | 2012-12-26 | Active Biotech AB | Deuterium-enriched 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide |
IN2014MN00333A (pl) | 2011-07-28 | 2015-09-25 | Teva Pharma | |
TW201400117A (zh) * | 2012-06-05 | 2014-01-01 | Teva Pharma | 使用拉喹莫德治療眼發炎疾病 |
BR112015010566A2 (pt) * | 2012-11-08 | 2017-07-11 | Clearside Biomedical Inc | métodos e dispositivos para o tratamento de doenças oculares em indivíduos humanos |
WO2015060812A1 (en) | 2013-10-21 | 2015-04-30 | Howard University | Treating ocular disease with efflux transporter inhibitors |
WO2015095772A2 (en) * | 2013-12-20 | 2015-06-25 | Emory University | Formulations and methods for targeted ocular delivery of therapeutic agents |
WO2017120355A1 (en) | 2016-01-06 | 2017-07-13 | Teva Pharmaceutical Industries Ltd. | Dihydroquinolines and uses thereof |
CN112996486A (zh) * | 2017-07-17 | 2021-06-18 | K·罗伊兹曼 | 包含细胞穿透肽的治疗剂的局部递送用于治疗年龄相关性黄斑变性及其它眼病 |
WO2019126431A1 (en) | 2017-12-22 | 2019-06-27 | Chemocentryx, Inc. | DIARYL SUBSTITUTED 5,5-FUSED RING COMPOUNDS AS C5aR INHIBITORS |
JP7254082B2 (ja) | 2017-12-22 | 2023-04-07 | ケモセントリックス,インコーポレイティド | C5aR阻害剤としてのジアリール置換6,5-縮合環化合物 |
MX2020010390A (es) | 2018-04-02 | 2021-01-15 | Chemocentryx Inc | Profarmacos de antagonistas de c5ar biciclicos fusionados. |
-
2020
- 2020-12-18 BR BR112022009192A patent/BR112022009192A2/pt unknown
- 2020-12-18 IL IL293469A patent/IL293469B2/en unknown
- 2020-12-18 DK DK20838435.4T patent/DK3886858T3/da active
- 2020-12-18 AU AU2020408179A patent/AU2020408179A1/en active Pending
- 2020-12-18 CN CN202080087752.XA patent/CN114845718A/zh active Pending
- 2020-12-18 KR KR1020227019983A patent/KR20220118419A/ko unknown
- 2020-12-18 ES ES20838435T patent/ES2921360T3/es active Active
- 2020-12-18 PL PL20838435.4T patent/PL3886858T3/pl unknown
- 2020-12-18 EP EP22167643.0A patent/EP4094765A1/en active Pending
- 2020-12-18 CA CA3157394A patent/CA3157394A1/en active Pending
- 2020-12-18 MX MX2022006439A patent/MX2022006439A/es unknown
- 2020-12-18 WO PCT/EP2020/086993 patent/WO2021123142A1/en active Application Filing
- 2020-12-18 EP EP20838435.4A patent/EP3886858B1/en active Active
- 2020-12-18 JP JP2022535637A patent/JP2023509336A/ja active Pending
-
2021
- 2021-07-02 US US17/366,979 patent/US11478465B2/en active Active
-
2022
- 2022-05-05 ZA ZA2022/04939A patent/ZA202204939B/en unknown
- 2022-09-07 US US17/939,109 patent/US20230066364A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
DK3886858T3 (da) | 2022-08-22 |
BR112022009192A2 (pt) | 2022-07-26 |
MX2022006439A (es) | 2022-07-19 |
ES2921360T3 (es) | 2022-08-24 |
AU2020408179A1 (en) | 2022-06-30 |
IL293469B2 (en) | 2024-04-01 |
IL293469B1 (en) | 2023-12-01 |
JP2023509336A (ja) | 2023-03-08 |
WO2021123142A1 (en) | 2021-06-24 |
US11478465B2 (en) | 2022-10-25 |
EP4094765A1 (en) | 2022-11-30 |
KR20220118419A (ko) | 2022-08-25 |
ZA202204939B (en) | 2023-12-20 |
US20210322400A1 (en) | 2021-10-21 |
EP3886858A1 (en) | 2021-10-06 |
CN114845718A (zh) | 2022-08-02 |
CA3157394A1 (en) | 2021-06-24 |
EP3886858B1 (en) | 2022-05-11 |
IL293469A (en) | 2022-08-01 |
US20230066364A1 (en) | 2023-03-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20190117T1 (hr) | iRNK TERAPIJA ZA LIJEČENJE BOLESTI OKA | |
IL277333A (en) | Methods for treating eye diseases | |
IL288523A (en) | Compounds for the treatment of pd-l1 diseases | |
IL276383B1 (en) | Treatment of ophthalmological diseases | |
EP3351219A4 (en) | MATERIAL FOR THE OPTICAL TREATMENT OF OCULAR DISEASES | |
SG11202006374VA (en) | Treatment of demyelinating diseases | |
IL282643A (en) | Soft combinations for the treatment of hematological diseases | |
GB2541840B (en) | Ophthalmic composition for the treatment of ocular infection | |
IL293469B2 (en) | Compounds for the treatment of eye diseases are associated with increased blood vessel formation | |
GB202015959D0 (en) | Treatment of diseases involving NAD | |
GB201805100D0 (en) | Treatment of sarcopenic diseases | |
IL289221A (en) | Compounds for the treatment of vision disorders | |
IL289436A (en) | Methods for treating eye diseases | |
EP3310396A4 (en) | THERAPEUTIC HYDROGELS BASED ON NANOFIBRES FOR THE LOCAL TREATMENT OF BRAIN DISEASES | |
IL282361A (en) | Treatment for neurological diseases | |
GB201914516D0 (en) | Treatment of eye disease | |
IL259381B (en) | Miravegron for the treatment of retinal diseases | |
PL3302463T3 (pl) | Zastosowanie 3 deoksyantocyjanidyn w leczeniu chorób oczu | |
EP3261635A4 (en) | Compounds for treating ocular diseases | |
GB201909438D0 (en) | Treatment of diseases | |
GB201904764D0 (en) | Treatment of ophthalmological conditions | |
GB201805556D0 (en) | Treatment of ophthalmological conditions | |
GB201811912D0 (en) | Treatment of disease | |
GB201811911D0 (en) | Treatment of disease | |
GB201810974D0 (en) | Treatment of disease |